image Follow Us:

Respiratio 2017; 7 (1-2): 91-101

KONCENTRACIJE TH1 I TH2 CITOKINA U MIKROCIRKULACIJI
TUMORA I U SERUMU KOD BOLESNIKA SA SCLC I NSLC

 

Karličić Vukoica¹, Stanojević Ivan², Sotirović Jelena³, Perić Aleksandar³, Jović Milena4 ,
Cvijanović Vlado5, Djukić Mirjana6 , Banović Tatjana7, Vojvodić Danilo
²

 

¹ Clinic for Lung diseases, Military Medical Academy, Belgrade, Serbia

²Institute for Medical Research, Military Medical Academy, Belgrade, Serbia

³ Department of Otorhinolaryngology,Military Medical Academy,Belgrade,Serbia

4 Institute of patology, Faculty of Medicine, University of Niš, Serbia

5 Klinika za grudnu hirurgiju VMA, Beograd, Srbija

6 Department for Toxicology, Faculty of Pharmacy, University of Belgrade, Serbia

7 Department of Immunology, SA Pathology, Royal Adelaide Hospital, Adelaide, Australia

 

Original Research

Naučni članak

doi: 10.26601/rsp.aprs.17.14

 

Sažetak

 

Uvod. Rak pluća predstavlja jedan od najsmrtonosnijih zloćudnih tumora, uz minimalne
ukupne stope preživljavanja bolesnika s uznapredovalom bolesti. Prema histološkoj strukturi se dele na SCLC i NSCLC. NSCLC se znatno razlikuju po biološkom ponašanju, kliničkom toku i ishodukao I odgovoru na terapiju. Od ranije je utvr
đena važna uloga Th1 limfocita u anti tumorskom odgovoru, dok limfociti Th2 negativno utiču na zaštitnu reakciju.


Cilj. Naš cilj je bio da utvrdimo ključne Th1 i Th2 citokine u mikrocirkulaciji tumora i u uzorcima seruma, te da poredimo profil citokina kod bolesnika s plućnim tumorima različitih histoloških karakteristika.

 

Materijal i metode. U istraživanje je uključen 41 bolesnik sa tumorima pluća III i IV kliničkog stadijuma. Histološki tip je određen imunohistohemijski, a veličina tumora, lokalizacija i širenje bolesti određene su radiološki. IL-2, IL-12, IFN-­, IL-4, IL-5, IL-6, IL-10 i IL-13 koncentracije su određene komercijalnim testovima protočnom citometrijom, u uzorcima seruma i mikrocirkulaciji tumora pluća.


Rezultati. Komparativnom analizom citokina u serumu bolesnika s rakom pluća je pokazala da bolesnici sa SCLC tumorima imaju značajnu koncentraciju IL-6 i IL-13. Bolesnici sa NSCLC imaju različite dominantne profile citokina. Uzorci kod pacijenata s NSCLC Ad sadržavale su visoke nivoe IL- 2, IFN-­,, IL-4, IL-10 i IL-13, pacijenti s NSCLC sq imaju visok IL-6 i IL-13, a pacijenti s NSCLC LC imaju visok nivo IL-2 i IFN-­. Profil citokina u mikrocirkulaciji tumora, bio je potpuno različit od profila citokina u serumu. Uzorci iz tumora, kod bolesnika sa SCLC imaju visoke nivoe IL-12, IFN-­, IL- 6 i IL-13. Pacijenti sa NSCLC su sa visokim nivoom IFN--­, IL-6 i IL-13, bolesnici sa NSCLC Sq su imali visoke vednosti IL-6 i IL-13, a bolesnici sa NSCLC LC imali visoke vrednosti IL-5 i IL-13. Analiza
citokina u oba uzorka istog pacijenta je pokazala odnose tumor / serum koje su karakteristične za različite histološke tipova tumora. Kod bolesnila sa SCLC tumorom značajno je povećan odnos vrednosti IL-2, IL-12, IFN-­, IL-4, IL-10 i IL-13 tumor / serum. Kod bolesnika sa Ad NSCLC značajno je povećana vrednost IL-12 i IL-6, kod bolesnika sa NSCLC sq povećana je vrednost IL-12 i IL-5, a NSCLC LC značajno povećana vrednost IL-5 i IL-13 kao i odnos vrednosti, tumor / serum.


Zaključak. Različiti histloški tipovi tumora pluća se razlikuju u pogledu nivoa Th1 i Th2 citokina. Na osnovu koncentracije citokina u sistemskoj cirkulaciji i mikrocirkulaciji tumora potvr
đena je dramatična i značajna razlika.

 

Ključne riječi: rak pluća, tumor, SCLC, NSCLC, citokin.

 

 Full Article (PDF)

 

 

LITERATURA:

 

1. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 2011;32:605-44.
[CrossRef]
PMid:22054876 PMCid:PMC3864624

 

2. Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol 2013;31:992-1001.
[CrossRef]
PMid:23401443

 

 

3. Asselin-Paturel, Echchakir H, Carayol G, Gay F, Opolon P, Grunenwald D, et al. Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients. Int J Cancer. 1998; 77(1):7-12.
[CrossRef]

 

 

4. Fischer JR, Darjes H, Lahm H, Schindel M, Drings P, Krammer PH. Constitutive secretion of bioactive transforming growth factor beta 1 by small cell lung cancer cell lines. Eur J Cancer 1994;30A(14):2125- 9.
[CrossRef]

 

 

5. Bennett WP, el-Deiry WS, Rush WL, Guinee DG Jr, Freedman AN, Caporaso NE, et al. p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cellung cancer. Clin Cancer Res 1998;4:1499-506.
PMid:9626468

 

 

6. Domagała-Kulawik J, Hoser G, Safianowska A, Grubek-Jaworska H, Chazan R. Elevated TGFbeta1 concentration in bronchoalveolar lavage fluid from patients with primary lung cancer. Arch Immunol Ther Exp (Warsz) 2006;54:143-7.
[CrossRef]
PMid:16648974

 

 

7. Andreev K, Graser A, Maier A, Mousset S, Finotto S. Therapeutical measures to control airway tolerance in asthma and lung cancer. Front Immunol 2012;3(Article 216):1-13.

 

 

8. Través PG, Luque A, Hortelano S. Macrophages, inflammation, and tumor suppressors: ARF, a new player in the game. Mediators Inflamm 2012;2012(Article 568783):1-11.

 

 

9. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-55.
[CrossRef]

 

 

10. Liu L, Ge D, Ma L, Mei J, Liu S, Zhang Q, et al. Interleukin-17 and prostaglandin E2 are involved in formation of an M2 macrophage-dominant microenvironment in lung cancer. J Thorac Oncol 2012;7:1091-100.
[CrossRef]
PMid:22534817 PMCid:PMC3378786

 

 

11. Wei H, Sun R, Xiao W, Feng J, Zhen C, Xu X, et al. Type Two Cytokines Predominance of Human Lung Cancer and Its Reverse by Traditional Chinese Medicine TTMP. Cellular & Molecular Immunology 2004;1(1):63-70.
PMid:16212923

 

 

12. Ma J, Liu H, Wang X. Effect of ginseng polysaccharides and dendritic cells on the balance of Th1/Th2 T helper cells in patients with non-small cell lung cancer. J Tradit Chin Med 2014; 34(6): 641-645.
[CrossRef]

 

 

13. Li J, Wang Z, Mao K, Guo X. Clinical significance of serum T helper 1/T helper 2 cytokine shift in patients with нon-small cell lung cancer. Oncology Letters 2014;8: 1682-1686.
PMid:25202391 PMCid:PMC4156275

 

 

14. Chen YC, Hsiao CC, Chen KD, Hung YC, Wu CY, Lie CH et al. Peripheral Immune Cell Gene Expression Changes in Advanced Non-Small Cell Lung Cancer Patients Treated with First Line Combination Chemotherapy. PLoS ONE 2013; 8(2): e57053.
[CrossRef]
PMid:23451142 PMCid:PMC3581559

 

 

15. Ghayumi MA, Mojtahedi Z, Fattahi MJ. Th1 and Th2 Cytokine Profiles in Malignant Pleural Effusion. Iran J Immunol 2011; 8 (4), 195-200.
PMid:22201616

 

 

16. Li R, Ruttinger D, Li R, Si LS, Wang YL. Analysis of the immunological microenvironment at the tumor site in patients with non-small cell lung cancer. Langenbeck's Archives of Surgery 2003;388(6)406– 412.
[CrossRef]
PMid:14504933

 

 

17. Zhang B, Yao G, Zhang Y, Gao J, Yang B, Rao Z, et al. M2-Polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma. Clinics 2011;66(11):1879-1886.
[CrossRef]
PMid:22086517 PMCid:PMC3203959

 

 

18. Hodge G, Barnawi J, Jurisevic C, Moffat D, Holmes M, Reynolds PN et al. Lung cancer is associated with decreased expression of perforin, granzyme B and interferon (IFN)-γ by infiltrating lung tissue T cells, natural killer (NK) T-like and NK cells. Clinical and Experimental Immunology 2014; 178: 79–85.
[CrossRef]
PMid:24894428 PMCid:PMC4360197

 

 

19. Chang CH, Hsiao CF, Yeh YM, Chang GC, Tsai YH, Chen YM et al. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy. Int J Cancer 2013; 132: 1977–1985.
[CrossRef]
PMid:23034889

 

 

20. Ito N, Nakamura H, Metsugi H and Ohgi S. Dissociation between T helper type 1 / type 2 differentiation and cytokine production of tumorinfiltrating lymphocytes in lung cancer patients. Surg Today 37: 390-394, 2001.
[CrossRef]
PMid:11381500

 

 

21. Ito N, Suzuki Y, Taniguchi Y, Ishiguro K, Nakamura H, Ohgi S. Prognostic significance of T helper 1 and 2 and T cytotoxic 1 and 2 cells in patients with nonsmall cell lungcancer. Anticancer Res. 2005;25(3B):2027-31.
PMid:16158940

 

 

22. Fritz JM, Dwyer-Nield LD and Malkinson MA. Stimulation of neoplastic mouse lung cell proliferation by alveolar macrophage-derived, insulin-like growth factor-1 can be blocked by inhibiting MEK and PI3K activation. Molecular Cancer 2011; 10:76.
[CrossRef]
PMid:21699731 PMCid:PMC3135566

 

 

23. Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall AL et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Gene & Development 2010; 24:241–255.
[CrossRef]
PMid:20080943 PMCid:PMC2811826

 

 

24. Roberts WK, Deluca IJ, Thomas A, Fak J, Williams T, Buckley N et al. Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells. J Clin Invest 2009; 119:2042– 2051.
[CrossRef]

 

 

25. Yanagawa H, Sone S, Takahashi Y, Haku T, Yano S, Shinohara T, et al. Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer 1995; 71: 1095-1098.
[CrossRef]
PMid:7734307 PMCid:PMC2033769

 

 

26. Zhao Z, Cheng X, Wang Y, Han R, Li L, et al. Metformin Inhibits the IL-6-Induced EpithelialMesenchymal Transition and Lung Adenocarcinoma Growth and Metastasis. PLoS ONE 2014; 9(4): e95884.
[CrossRef]
PMid:24789104 PMCid:PMC4005743

 

 

27. Wójcik E, Jakubowicz J, Skotnicki P, SasKorczyńska B, Kulpa JK.IL-6 and VEGF in Small Cell Lung Cancer Patients. Anticancer Research 2010; 30: 1773-1778.
PMid:20592377

 

 

28. Huang M, Wang J, Lee P, Stiantila S, Mao JT, Meissner H et al. Human Non-Small Cell Lung Cancer Cells Express a Type 2 Cytokine Pattern. Cancer Research 1995; 55: 3847-3853.
PMid:7641203

 

 

29. Fujisawa T, Joshi B, Nakajima A, Puri RK. A Novel Role of Interleukin-13 Receptor α2 in Pancreatic Cancer Invasion and Metastasis. Cancer Res 2009;69(22):8678–85.
[CrossRef] https://doi.org/10.1158/0008-5472.CAN-09-2100
PMid:19887609

 

 

30. Fujisawa T, Joshi BH, Puri RK IL-13 regulates cancer invasion and metastasis through IL-13Ra2 via ERK/AP-1 pathway in mouse model of human ovarian cancer. Int. J. Cancer 2012, 131: 344–356.
[CrossRef]
PMid:21858811

 

 

Submitted: April 10th, 2017
Accepted: May 10th, 2017

 

 

V. Karličić
Klinika za plućne bolesti,
VMA, Beograd, Srbija
This email address is being protected from spambots. You need JavaScript enabled to view it.
+381637750096

Travel Turne Tranzito